title: [New therapeutic strategies and current research in inoperable locally advanced non small-cell lung cancers (stage IIIB)].
abstract: Treatment of patients with inoperable locally advanced non small-cell lung cancer (NSCLC) remains disappointing with less of 5% of patients alive at 5 years. Both initial local control and circumvention of concomitant undetectable metastatic chemoresistant cells are the critical targets for the oncologists in charge of this disease. Results of a recent meta-analysis including 22 randomized studies comparing standard treatment (i.e. radiotherapy) to sequential chemoradiotherapy have undoubtabely well defined the role of cisplatine-containing chemotherapy in stage IIIB NSCLC, even if the 5 year survival benefit remains modest. However, high complete response rates and prolonged overall survival were observed with combinations of new promising chemotherapy regimens and new fractionated radiation schedules in several phase II studies. These results have to be corroborated by prospective randomized trials. Integration of more aggressive and more toxic strategies such as radical surgery in these initial inoperable locally advanced NSCLC are evaluating. Around these conventional therapies, the stage IIIB NSCLC represent a favoured target to elaborate innovative therapeutic approaches based on emergence of biotherapies as recombinant cytokines, antitumoral vaccine and gene therapy programs. The contribution of these new therapeutic options opens new directions in the therapeutic strategy and leads to hope a new promising era in the management and outcome of patients with these tumors.
authors.affiliation: Département de médecine, Institut Gustave-Roussy, Villejuif, France.
authors.forename: A
authors.initials: A
authors.lastname: Le Cesne
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: D
authors.initials: D
authors.lastname: Grunenwald
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: P
authors.initials: P
authors.lastname: Girard
authors.forename: J J
authors.initials: JJ
authors.lastname: Bretel
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D011994:Recombinant Proteins; D002945:Cisplatin
vernacular_title: Stratégies thérapeutiques récentes et voies de recherche actuelles dans les cancers du poumon inopérables (stade IIIB) non à petites cellules.